Publicaciones en colaboración con investigadores/as de Oregon Health & Science University (11)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2021

  1. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  2. Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model

    Journal of Inherited Metabolic Disease, Vol. 44, Núm. 6, pp. 1369-1381

2016

  1. Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

    Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1

  2. Perspectives in immunotherapy: Meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015

    Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1

2015

  1. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

    Nature Medicine, Vol. 21, Núm. 6, pp. 555-559

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508

  2. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

    Journal of Translational Medicine, Vol. 12, Núm. 1

2012

  1. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: A phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

    British Journal of Cancer, Vol. 107, Núm. 5, pp. 808-813

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine